The benefits of GLP-1 drugs beyond obesity

2024/07/18 by Daniel J. Drucker · 1 voice · 4 citations
Medicine · #Diabetes Treatment and Management #Diet and metabolism studies #Pharmacology and Obesity Treatment

paper · doi:10.1126/science.adn4128

openalex publication_date 2024/07/18 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Glucagon-like peptide-1-based medicines have weight loss-independent actions.

Cited by

• Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
• Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
• Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study
• Senotherapeutics for metabolic disease and diabetic complications

Discussions

• will retract if after reading, this convinces me something else is going on [bsky, 1 points, 0 comments]

Related

• Therapies based on GLP-1 receptor agonists: significance, challenges, and opportunities
• GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
• GLP-1 physiology and pharmacology along the gut-brain axis
• Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
• Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity